DAFNA Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

DAFNA Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$945K	Sell	98,724 -42,321	-30%	-$480K	0.22%	62
2025 Q4	$1.15M	Buy	141,045 +36,374	+35%	+$419K	0.27%	59
2025 Q3	$1.26M	Sell	104,671 -30,600	-23%	-$322K	0.31%	57
2025 Q2	$1.37M	Sell	135,271 -106,729	-44%	-$717K	0.38%	48
2025 Q1	$1.35M	Buy	+242,000	New	+$2.12M	0.38%	46
2024 Q3	–	Sell	-36,000	Closed	-$255K	–	85
2024 Q2	$255K	Buy	+36,000	New	+$322K	0.06%	77
2024 Q1	–	Sell	-72,797	Closed	-$670K	–	79
2023 Q4	$670K	Buy	+72,797	New	+$526K	0.16%	62
2023 Q2	–	Sell	-170,326	Closed	-$971K	–	77
2023 Q1	$971K	Sell	170,326 -93,911	-36%	-$491K	0.29%	46
2022 Q4	$1.56M	Sell	264,237 -149,289	-36%	-$504K	0.44%	50
2022 Q3	$1.32M	Sell	413,526 -2,400	-0.6%	-$9.61K	0.36%	51
2022 Q2	$1.86M	Buy	+415,926	New	+$1.66M	0.51%	48

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

DAFNA Capital Management's ORIC Position: Q1 2026 in Review

DAFNA Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 30% in Q1 2026, selling an estimated $480K and leaving 98,724 shares worth $945K. The position accounts for 0.22% of the portfolio, ranked #62.

DAFNA Capital Management first reported a position in ORIC in Q2 2022 and has held it in 11 quarters since. The position peaked at $1.86M in Q2 2022. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

DAFNA Capital Management held 98,724 shares of Oric Pharmaceuticals worth $945K as of Q1 2026.
DAFNA Capital Management sold 42,321 Oric Pharmaceuticals shares in Q1 2026, an estimated $480K.
Oric Pharmaceuticals made up 0.22% of DAFNA Capital Management's portfolio in Q1 2026, its #62 holding.
DAFNA Capital Management first reported a position in Oric Pharmaceuticals in Q2 2022 and has held it in 11 quarters since.
DAFNA Capital Management's Oric Pharmaceuticals position peaked at $1.86M in Q2 2022.
182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.